In GBM, our lab previously showed that silencing or pharmacological inhibition of TRPM7 reduced the levels of p-Akt and p-ERK1/2, and consequently, downregulated the PI3K/Akt and MAPK/ERK pathways [4, 5]. The gene discussed is AKT1; the disease is glioblastoma.